Nearly 18.4 billion painkiller market, two domestic enterprises into the top three sales

"
Pharmaceutical Network Market Analysis" Recently, Yangzijiang's hydrochloric acid nabutyl injection 3 class of generic listing application was accepted by CDE, the product is currently only a blessing to obtain approvalThe market for end-of-life painkillers in China's public medical institutions in 2019 is close to 18.4 billion, according to Minnet.comIn terms of market pattern, there are three pharmaceutical companies with sales of more than 1 billion yuan, with total sales of more than 10.4 billion yuan in 2019, and the market share has risen to about 57%One of the Top3 companies is Bayer, and the other two are domestic, namely Yangzijiang Pharmaceuticals and Hengruiamong them, Yangzijiang Pharmaceuticals firmly in the "one brother" statusIn 2015-2019, the market share grew rapidly from 30.26% in 2015 to 36.94% in 2019Dizozin injections are the main products of Yangzijiang Pharmaceuticals in the field of painkillers, a variety of pains developed by Wyeth-Ayerst Laboratories and used to treat various types of pain with opioid analgesicsYangzijiang Pharmaceuticals' Dizozin injection was launched in October 2009, with its high analgesic activity and the advantages of less adverse reactions such as respiratory suppression, constipation, analgesic tolerance and addictionSales grew rapidly from RMB602 million in 2013 to RMB1,863 million in 2018, with growth slowing in 2018-2019 but not unchangingIn 2019, the terminal of China's public medical institutions has soared to 6 billion yuanit is worth noting that in the recent years, many provinces have published the local medical insurance "retirement" rules, it is expected that the future sales of Dizosin injection will be affected to a certain extent, in addition to Yangzijiang Pharmaceuticals, there are Tianjin Pharmaceutical Research Institute, Jiangsu Enhua Pharmaceuticals and other pharmaceutical companies have submitted the listing application for the variety, Nanjing Youke Pharmaceuticals 6 types of imitation has also been approved for listingThe market pattern or change of the future dizosin injectionanaesthetic business is the second-largest core business of Hengrui Pharmaceuticals, mainly related to surgical anesthesia-related drugs, including heptafluorane (inhalation anesthesia), right metoramide (anaesthetic sedation), shun aquuk (mymitol), butrophinor (analgesic) four core varietiesHengrui Pharmaceuticals' anaesthetic business has exceeded 1 billion yuan since 2018 and rose to 1.66 billion yuan in 2019, a growth rate of more than 37% Market share also rose from 5.74% in 2015 to 9.03% in 2019 , the analgesic stonophine belongs to the second class of psychotropic drugs in our country The oreic acid butumorphine injection is a heavyweight product of Hengrui, surpassing 1 billion yuan in the terminal of china's public medical institutions in 2018 and rising to 1.6 billion in 2019 Growth has remained above 30% in the past two years Not only that, Hengrui has also increased the layout of the city's public hospitals, from about 74% in 2015 to more than 80% in the last two years In recent years, the unit price of this variety has been increasing continuously The industry believes that sales and gross margins will continue to grow in the future as the adjusted price of the product wins in more provinces -Minnet.com data show that as of July 1, 2020, three products were involved in the adoption and adoption of consistent evaluations of painkillers In addition, the review of the painkiller consistency evaluation supplement application and the new classification of imitation listing application sits involving 21 products, of which 18 are currently no enterprise evaluation, China's public medical institutions terminal TOP10 products, including dizosin injection, aspirin intestinal tablets, hydroxycodone tablets, hydroxyl ketone hydrochloride hydrochloride injections Predictably, with the subsequent listing of more varieties, the competition in the painkiller market will become more intense.